Drugs that contain Meropenem; Vaborbactam

1. List of Vabomere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680136 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9694025 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(8 years from now)

US10561675 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(8 years from now)

US10183034 REMPEX Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Aug, 2031

(8 years from now)

US11007206 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(8 years from now)

US10172874 REMPEX Pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Aug, 2031

(8 years from now)

US11376237 REMPEX Methods of treating bacterial infections
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 29, 2022
Generating Antibiotic Incentives Now (GAIN) Aug 29, 2027

NCE-1 date: August, 2026

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of patients 18 years of age and older with complicated urinary tract infections caused by susceptible microorganisms; Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae species complex; Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, enterobacter cloacae species complex with meropenem & vaborbactam as specified; Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species complex with meropenem & vaborbactam as specified

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in